Business
Global Business Accelerator Programme in Japan
Global Business Accelerator Programme in Japan.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 8172C N4 Pharma PLC 24 January 2018 \n\nN4 Pharma Plc\n(\"N4 Pharma\" or the \"Company\")\nGlobal Business Accelerator Programme: Visit to Japan\n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces that it is among a group of innovative UK companies operating in the cell and gene therapy sector chosen to receive funding from Innovate UK, the UK's innovation agency, to attend the Global Business Accelerator Programme Cell and Gene Therapy Visit to Japan.\nThe Company will visit Japan from 19 to 24 February 2018 and attend the Cell and Gene Therapy Matchmaking event and Medical Japan 2018. In addition, the Company will also receive pre- and post-visit support to help follow up on meetings held during the events.\nNigel Theobald, CEO of N4 Pharma, commented: \"We are delighted to have been chosen to join this visit and to have the opportunity to attend these events and present Nuvec® to relevant companies in Japan.\nWith the Asia-Pacific DNA vaccine market forecast to grow at a CAGR of 45.85% through to 2025*, driven by factors such as a growing population with unmet medical needs and increasing awareness regarding the advantages of vaccines, Japan represents an exciting potential future market for N4 Pharma's offerings.\"\n*Source: INK Wood Asia-Pacific DNA Vaccines Market forecast 2017-2025\nEnquiries:\n\n\n\n\nN4 Pharma Plc\nNigel Theobald, CEO\n\n\n \nVia Alma PR\n\n\n\n\nStockdale Securities\nTom Griffiths\n\n\nTel: +44(0)207 601 6100\n \n\n\n\n\nBeaufort Securities\nElliot Hance\n\n\nTel: +44(0)207 382 8300\n \n\n\n\n\nAlma PR\nJosh Royston\nRobyn Fisher\n\n\n \nTel: +44(0)778 090 1979\nTel: +44(0)754 070 6191\n\n\n\n\n \nAbout N4 Pharma\n \nN4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.\nN4 Pharma's reformulation work falls under two divisions:\n• generic, already commercialised, drugs; and\n• delivery of novel and existing vaccines.\nN4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at w...